Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phorbol esters and D2-dopamine receptors.

L X Cubeddu1, T W Lovenberg, I S Hoffman

  • 1Division of Clinical Pharmacology, School of Medicine, University of Carolina, Chapel Hill, North Carolina.

The Journal of Pharmacology and Experimental Therapeutics
|November 1, 1989
PubMed
Summary

4-beta-Phorbol-12,13-dibutyrate (PDBu) enhances dopamine release in rabbit brain regions. PDBu also antagonized D2 dopamine receptor agonists, suggesting a complex interaction within the dopaminergic system.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microalbuminuria: do we need a new threshold?

Journal of human hypertension·2008
Same author

Effects of lifestyle changes and metformin on salt sensitivity and nitric oxide metabolism in obese salt-sensitive Hispanics.

Journal of human hypertension·2007
Same author

Increased blood pressure reactivity to dietary salt in patients with the metabolic syndrome.

Journal of human hypertension·2007
Same author

NAD(P)H oxidase p22phox gene C242T polymorphism, nitric oxide production, salt sensitivity and cardiovascular risk factors in Hispanics.

Journal of human hypertension·2006
Same author

Endothelial nitric oxide synthase polymorphism, nitric oxide production, salt sensitivity and cardiovascular risk factors in Hispanics.

Journal of human hypertension·2004
Same author

Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist.

British journal of pharmacology·2004

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Protein kinase C (PKC) activators influence neurotransmitter release.
  • Dopamine (DA) and acetylcholine (ACh) are key neurotransmitters in the brain.
  • D2 dopamine receptors modulate DA and ACh release.

Purpose of the Study:

  • To investigate the effect of PDBu on DA and ACh release.
  • To examine the interaction between PDBu and D2 DA receptor agonists.

Main Methods:

  • Electrical stimulation of rabbit striatum and prefrontal cortex slices.
  • Measurement of DA and ACh release.
  • Application of PDBu, D2 DA receptor antagonists (sulpiride), uptake inhibitors (nomifensine), and D2 DA agonists (LY-171555, bromocriptine, apomorphine).
  • Pretreatment with reserpine and alpha-methyl-p-tyrosine to deplete endogenous DA.

Related Experiment Videos

Main Results:

  • PDBu enhanced stimulation-evoked DA release in the striatum and prefrontal cortex, but only slightly enhanced ACh release.
  • PDBu's enhancement of DA release was frequency-dependent.
  • D2 DA agonists inhibited DA and ACh release, an effect antagonized by PDBu.
  • PDBu's antagonism of agonist effects was independent of endogenous DA levels.

Conclusions:

  • PDBu, a PKC activator, modulates dopaminergic neurotransmission.
  • PDBu facilitates DA release and antagonizes D2 DA receptor-mediated inhibition of DA and ACh release.
  • These findings suggest a complex interplay between PKC and D2 DA receptor signaling pathways.